Benzinga | Jun 7, 2021 09:01AM EDT

Atossa Therapeutics To Release Final Data From Phase 2 Study Of Endoxifen Administered To Breast Cancer Patients Prior To Surgery At Webinar at 8 a.m. PT June 9

Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in oncology and infectious disease with a current focus on breast cancer and COVID-19, announces that it will hold a webinar at 8 am Pacific Time on June 9, 2021 to release and discuss final data from its Phase 2 study of Endoxifen administered to breast cancer patients prior to surgery. The webinar will be attended by Dr. Steven Quay, CEO and President, Kyle Guse, CFO and General Counsel, and Dr. B. Heather Fraser, VP Clinical, Regulatory and CMC.

To register to join the complimentary ZOOM-based webinar event, please visit Tribe Public LLC at ATOS.TribePublic.com. Registered participants may email questions for Atossa's management to Tribe Public prior to the event at research@tribepublic.com or share their questions via the ZOOM chat feature during the event. Tribe Public's Managing Member, John F. Heerdink, Jr., will host the event and relay questions to management.